ideasIdea
Trial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer
For rare cancers, the patient is often at a hospital that has no trial. A ready-made kit with the protocol, consent forms, database and shipping already set up would let that hospital enrol them within days.
A cooperative group or rare-cancer consortium maintains modular, pre-approved protocol packages for rare histologies: template protocol with pre-negotiated ethics approval under a central IRB, eConsent, cloud EDC, sample-shipping kits and a remote investigator-of-record model where local clinicians act as sub-investigators. Combined with just-in-time activation, the kit lets any accredited hospital enrol its one patient.
Hypothesis
Rare-cancer trials using a trial-in-a-box model will enrol from at least three times as many sites and reach accrual targets faster than conventional multicentre rare-cancer trials.
Rationale
Rare-cancer trials fail on accrual because patients are scattered; every patient not enrolled is a large fraction of the target. Paediatric oncology achieves high enrolment through standardised cooperative-group infrastructure that adult rare-cancer trials lack.
What would test it
Deploy a kit for one rare adult sarcoma or neuroendocrine subtype across a national network and compare enrolment per eligible incident case with a historical trial in the same subtype.
Maturity
speculative
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
3
Bottlenecks it attacks
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.